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Abstract
The microtubule-associated protein tau exists as six isoforms created through the splicing of the
second, third, and tenth exons. The isoforms are classified by their number of N-terminal exons
(0N, 1N or 2N) and by their number of microtubule-binding repeat regions (3R or 4R).
Hyperphosphorylated isoforms accumulate in insoluble aggregates in Alzheimer’s disease and
other tauopathies. These neurodegenerative diseases can be categorized based on the isoform
content of the aggregates they contain. Hyperphosphorylated tau has the general characteristics of
an upward electrophoretic shift, decreased microtubule binding, and an association with
aggregation. Previously we have shown that a combination of seven pseudophosphorylation
mutations at sites phosphorylated by GSK-3β, referred to as 7-Phos, induced several of these
characteristics in full-length 2N4R tau and led to the formation of fewer but longer filaments. We
sought to determine whether the same phosphorylation pattern could cause differential effects in
the other tau isoforms, possibly through varied conformational effects. Using in vitro techniques,
we examined the electrophoretic mobility, aggregation properties and microtubule stabilization of
all isoforms and their pseudophosphorylated counterparts. We found that pseudophosphorylation
affected each isoform, but in several cases certain isoforms were affected more than others. These
results suggest that hyperphosphorylation of tau isoforms could play a major role in determining
the isoform composition of tau aggregates in disease.
Tau is a microtubule-associated protein typically found in neurons with a primary function
of assisting in the assembly and stabilization of microtubules (1). The protein also interacts
with the cellular membrane through components such as annexin A2 (2). In addition, tau
associates with certain cellular kinases and has been shown to affect the localization of
some, including fyn (3, 4). The protein, tau, exists as six isoforms created through
alternative mRNA splicing of the second, third, and tenth exons (5). The second and third
exons reside near the N-terminus of the protein and isoforms can be classified based on the
presence or absence of these exons. If both exons are present the protein is referred to as 2N,
if only the second exon is present it is known as 1N, and if neither is present it is classified
as 0N. Exon 10 contains one of four microtubule-binding repeat regions (MTBR). If this
exon is present in the isoform the protein is referred to as 4R and if it is absent the protein is
classified as 3R (6).
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In some disease states tau dissociates from microtubules and aggregates inside of neurons,
leading to neurodegeneration (7, 8). This group of neurodegenerative disorders is
collectively known as tauopathies. Tauopathies can be classified based on the isoform
content and phosphorylation pattern found in tau aggregates (7). While aggregates from
Class I tauopathies contain all six isoforms, Class II aggregates are characterized by a larger
ratio of 4R to 3R tau, and Class III tauopathies are associated with aggregates containing
mostly 3R isoforms. The Class III tauopathies are also characterized by a lack of
phosphorylation at the 262 and 356 serine residues (9, 10). Aggregates from the fourth class
of tauopathies typically contain only 0N isoforms (7). The various tauopathies can give rise
to vastly different pathological effects and the changes in isoform content seen in the
aggregates could play a role in affecting these variations. While the root causes of
differential isoform inclusion into pathological aggregates are unknown, it is possible that
phosphorylation of the isoforms could differently alter their function and activity sufficiently
to contribute to this phenomenon.
Several links between phosphorylation of tau and the pathology of Alzheimer’s disease
(AD) and other tauopathies have been described. A potential important factor is the increase
in hyperphosphorylated tau found in AD-affected brains. Hyperphosphorylated tau can be
identified by an upward electrophoretic mobility shift, even in the presence of SDS, and a
decreased ability to stabilize microtubule assembly (11, 12). It is probable that several
kinases and phosphatases are involved in generating hyperphosphorylated tau, but one
kinase likely to be involved is glycogen synthase kinase 3β (GSK-3β) due to its association
with the formation of neurofibrillary tangles and paired-helical filaments found in AD (13–
15). In addition, several sites commonly found to be phosphorylated in pathogenic tau are
known to be phosphorylated by GSK-3β (16, 17).
While links to phosphorylation and certain kinases are known, it can be difficult to study the
effects that specific phosphorylation sites can have on the function and in vitro aggregation
of the protein because it is nearly impossible to control the level and specific location of
kinase activity on tau due to the large number of phosphorylation sites and the relative
promiscuity of kinases toward tau (18–21). This can complicate collection and interpretation
of data. One method used to circumvent this issue is to utilize site-directed mutagenesis to
create pseudophosphorylation mutants by changing a serine or threonine to an aspartic acid
or glutamic acid in order to mimic the size and the shape of a phosphate molecule (22, 23).
Although the effects of pseudophosphorylation may not completely replicate the effects of
actual phosphorylation events, the technique has previously been utilized effectively to
examine conformational changes in the protein and behavioral effects that may arise from
these changes (24–30).
A combination of pseudophosphorylation mutations, referred to as 7-Phos for the seven
specific sites mutated, were previously created in 2N4R full-length tau (27). The 7-Phos
mutation alters the following residues, numbered according to their position in 2N4R tau:
S199E, S202E, T205E, T231E, S235D, S396E, and S404E. Five of these sites are
phosphorylated by GSK-3β when the kinase is incubated in vitro with arachidonic acid-
induced pre-polymerized tau and the S202 and S235 sites are often phosphorylated in
conjunction with the S199 and T231 sites (13, 27). All of the selected sites are
phosphorylated at elevated levels in AD and the combination of these mutations replicated
several aspects of pathogenic tau (21). The 7-Phos mutations, in 2N4R tau, were shown to
induce an electrophoretic mobility shift similar to that of the hyperphosphorylated protein
seen in AD. Additionally, the 7-Phos mutation caused a decrease in the 2N4R tau isoform’s
affinity for microtubules and inducer-initiated nucleation of tau polymerization (27).
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As described above, the pathology of tauopathies can vary based on the isoform content of
their aggregates and tau phosphorylation patterns differ between the four classes of the
diseases as well. The six isoforms have differences in their primary structures which could
place the same phosphorylation sites in different structural contexts. Therefore,
phosphorylation at the same sites, but in different isoforms, could have widely varied effects
on their conformation. These conformational changes could be sufficient to cause some
isoforms to dissociate from microtubules and aggregate while others maintain their normal
function, as seen in some tauopathy classes.
In this study we demonstrate that the 7-Phos mutation does affect the isoforms differently.
The SDS-resistant upward shift in electrophoretic mobility was present in all isoforms but
differed in magnitude. The mutation enhanced the polymerization of isoforms such as 0N4R
while greatly inhibiting the aggregation of the 3R isoforms. The mutation also decreased the
microtubule stabilization function of all isoforms but affected 0N4R less than the other five.
These results suggest that phosphorylation patterns generated by the same set of kinases or
phosphatases could be sufficient to increase the propensity of some isoforms to aggregate




All wild-type and pseudophosphorylated mutant proteins were expressed and purified as
described previously (31). The mutations were made utilizing the Quikchange site-directed
mutagenesis kit from Stratagene (La Jolla, CA). The following mutations were made in each
of the 6 isoforms in order to create the “7-Phos” mutants: S199E, S202E, T205E, T231E,
S235D, S396E, and S404E. Polymerization was induced using arachidonic acid (ARA) from
Cayman Chemicals (Ann Arbor, MI).
SDS-PAGE
Each protein sample was incubated in buffer containing 2% SDS and 1% β-mercaptoethanol
and then boiled for five minutes. One μg of each protein was loaded onto a 10% SDS-PAGE
and resolved through electrophoresis. The urea-denatured protein samples were incubated in
buffer containing 2% SDS, 1% β-mercaptoethanol, and 6 M urea (27). The protein samples
were resolved on a 10% SDS-PAGE with 6 M urea and stained with Coomassie Brilliant
Blue R-250.
ARA-induced Polymerization
Recombinant tau protein was incubated in polymerization buffer containing 10 mM HEPES
(pH 7.64), 5 mM DTT, 100 mM NaCl, 0.1 mM EDTA, and 3.75% ethanol. Arachidonic acid
was used as an inducer of tau polymerization. The effects of altering protein or ARA levels
were found by varying final protein concentration from 0 to 4 μM with 75 μM ARA or
varying the final ARA concentration from 0 to 150 μM with 2 μM protein (14). Based on
these results a combination of 2 μM protein and 75 μM ARA were used in subsequent
experiments in order to approach maximum polymerization for each tau isoform and its
corresponding 7-Phos mutant.
Thioflavin S fluorescence
Polymerization was measured by utilizing staining with thioflavin S (ThS) from Sigma-
Aldrich (St. Louis, MO). Polymerization reactions were incubated for 18 hours at 25 °C.
ThS was then added to the reactions in 96-well plates to a final concentration of 20 μM. The
shift in fluorescence was measured with an excitation wavelength of 440 nm and an
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emission wavelength of 520 nm using a Cary Eclipse Fluorescence Spectrophotometer
(Varian Analytical Instruments, Walnut Valley, CA). The PMT voltage was set to 650 V but
the procedure was otherwise performed as described earlier (31).
Right-angle Laser Light Scattering
Polymerization reactions were transferred to 5 mm x 5 mm optical glass fluorometer
cuvettes (Starna Cells, Atascadero, CA). The cuvettes were placed in the path of a 12 mW
solid state laser at λ = 532 nm and operating at 7.6 mW (B&W Tek, Inc., Newark, DE). The
level of polymerization was measured by capturing images of light scattered perpendicular
to the beam using a SONY XC-ST270 digital camera. The images were captured at an
aperture setting of f5.6–8. The intensities of the images were quantified using Adobe
Photoshop CS5 version 12.0.1 (32, 33).
ARA-Induced Polymerization Kinetics
Polymerization reactions with 2 μM protein and 75 μM ARA, at the same reaction
conditions described earlier, were mixed in 5 mm x 5 mm optical glass fluorometer cuvettes.
Polymerization was measured at regular time intervals through right-angle laser light
scattering (LLS) until an apparent steady-state was reached (27).
Transmission Electron Microscopy
The polymerization reaction samples were diluted 1:10 in polymerization buffer with
glutaraldehyde added to a final concentration of 2%. After the five minute fixation with
glutaraldehyde, 10 μL of each sample was added to a formvar carbon-coated grid for one
minute. The grid was blotted on filter paper, washed with water, blotted, washed with 2%
uranyl acetate, and blotted dry again. The grid was then stained with 2% uranyl acetate for
one minute and blotted dry on the filter paper again. The grids were examined with a
TECNAI G2 20 electron microscope (FEI Co., Hillsboro, OR) and images were taken with
the Gatan Digital Micrograph imaging system. The images were collected at a magnification
of 3600X. The filament numbers and areas were quantified through the use of Image-Pro
Plus 6.0 (27).
Tubulin Polymerization Assay
Polymerization of tubulin was measured by utilizing the Tubulin Polymerization Assay kit
from Cytoskeleton, Inc. (Denver, CO). The reactions were measured in 96-well Costar black
polystyrene flat-bottom plates (Corning, Inc., Corning, NY). Each well contained GTP at 1
mM and tubulin at 2 mg/mL in an 80 mM PIPES buffer (pH 6.9) with 2 mM MgCl2 and 0.5
mM EGTA. Each of the wild-type or 7-Phos isoforms was added to a different well at a final
concentration of 1 μM. Another well contained 1 μM paclitaxel in order to act as a positive
control for polymerization and as a standard for normalizing the results for each of the other
reactions. The two negative control reactions contained tubulin with no additional
compound added. Upon addition of the protein or control reagent to the other wells, the plate
was placed at 37 °C and shaken for 5 seconds in a FlexStation II Fluorometer (Molecular
Devices Corporation, Sunnyvale, CA). The fluorescence was measured every minute for one
hour with a λex of 355 nm and a λem of 455 nm. The resulting data were fit to the Gompertz
equation  as described in (27). The maximum amount of polymerization is found
as a, the time from the initiation of the reaction to when polymerization is measured, or lag
time, is calculated as ti − b, and kapp is equal to 1/b and proportional to the maximum rate of
polymerization. These parameters were used to describe the characteristics of the
polymerization curve.
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Generation of 7-Phos Mutants for All Tau Isoforms
Pseudophosphorylation mutants were generated in all six tau isoforms by making S199E,
S202E, T205E, T231E, S235D, S396E, and S404E mutations (Figure 1A). The mutants
were analyzed by SDS-PAGE and found to exhibit an upward mobility shift as had been
previously described for the 2N4R isoform (27). All 7-Phos isoforms displayed a decrease in
electrophoretic mobility when compared to their corresponding wild-type protein (Figure
1B). However, upon addition of 6 M urea, the upward mobility shift in the 7-Phos proteins
was still present but largely decreased for all isoforms (Figure 1C). The electrophoretic
shifts, in the absence of urea, were similar for all isoforms but slightly increased with the
presence of additional N-terminal exons (Figure 1D). Because the wild-type and 7-Phos
proteins have more similar migration distances in the presence of 6 M urea, but not in its
absence, it is likely that the 7-Phos mutations are inducing an SDS-resistant conformational
change in the proteins that can be interrupted with urea. This pseudophosphorylation-
induced conformational change is the cause of the slowed electrophoretic migration and is
similar to the retardation evident in hyperphosphorylated tau associated with disease.
Pseudohyperphosphorylation differentially affects ARA-induced polymerization of
isoforms
In vitro experiments were performed to determine the effects of the 7-Phos mutation on the
ARA-induced polymerization of the six isoforms. The concentration of the inducer was held
constant and the protein concentration varied from 0–4 μM. The amount of polymerization
generally increased with increases in protein concentration (Figures 2 and 3). The 7-Phos
mutants containing only three MTBRs, or 3R isoforms, polymerized less than their
corresponding wild-type 3R isoforms when measured by ThS staining (Figure 2A-C) and
right-angle LLS (Figure 3A-C). In contrast, the 1N4R and 2N4R 7-Phos isoforms
polymerized more similarly to their corresponding 1N4R and 2N4R wild-type proteins
(Figures 2E-F and 3E-F) as compared to the 3R isoforms (compare Figures 2A-C, E-F and
3A-C, E-F). Unlike any of the other isoforms, the 0N4R 7-Phos protein polymerized more
than its corresponding wild-type for most protein concentrations (Figures 2D and 3D).
To determine whether the 7-Phos modification altered the response to different
concentrations of the inducer, the protein concentration was held constant and the
concentration of inducer was varied from 0 μM to 150 μM. Data of this nature generally has
a biphasic shape, with increasing polymerization up to a maximum level as the inducer
concentration increases. After this maximum of polymerization is reached, any further
addition of inducer decreases the amount of polymerization compared to the peak. The
biphasic nature of inducer-mediated tau polymerization has been previously reported (14,
34). The polymerization for each of the 3R 7-Phos isoforms was lower than their
corresponding non-modified 3R proteins, as measured by ThS staining (Figure 4A-C).
Additionally, the 3R 7-Phos isoforms required a higher inducer concentration to reach
maximum polymerization than the 3R wild-type isoforms. When the polymerization was
measured by LLS, very little polymerization was detected for any of the 3R 7-Phos isoforms
while the wild-type 3R isoforms also displayed the biphasic curve but with a sharp increase
at the highest inducer concentrations (Figure 5A-C). Because these increases in light
scattering, primarily seen at the 150 μM ARA concentration, are not replicated when
measured by ThS staining (Figure 4A-F) or transmission electron microscopy (data not
shown) they are likely due to formation of ARA micelles and not increased tau
polymerization. Additionally, in Figures 4 and 5, we are greatly altering the ARA to protein
ratio which has been shown to affect ThS and LLS readings differently (14).
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The polymerization of 0N4R 7-Phos was greater than its corresponding wild-type at the
higher inducer concentrations tested when measured by ThS fluorescence (Figure 4D).
However, the LLS measurements indicated that polymerization of the 0N4R 7-Phos isoform
was greater than that of the 0N4R wild-type isoform at 50 and 100 μM ARA but less than
wild-type at the higher concentrations tested. The polymerization curves for 1N4R and
2N4R wild-type and 7-Phos variants were more similar to one another than what was
observed for the other isoforms (Figure 4E-F and Figure 5E-F).
Any discrepancies between ThS staining and LLS readings could be due to subtle
differences in how measurements from the two methods are affected by changes in length or
other morphological characteristics in the population of filaments (14, 35–37). Fewer, but
longer, filaments may decrease the amount of light scattered but could have little change in
ThS binding if the total amount of polymerization is similar. In addition, changes in
morphology, such as a change in the β-sheet structure or the formation of straight filaments
rather than paired helical filaments, could also affect the affinity of ThS binding. Factors
other than morphology changes, such as the formation of ARA micelles, could also have an
effect on LLS values. Because of these challenges we believe that utilizing both methods, as
well as transmission electron microscopy, will give us a clearer picture of alterations in the
polymerization ability of these tau variants.
Visual inspection of the above curves revealed that most proteins at 2 μM concentration had
a peak in polymerization either at or close to 75 μM ARA. As these polymerization
conditions are routinely used for in vitro tau polymerization reactions, they were chosen for
further analysis of the effects of the 7-Phos modification on the tau isoforms (27, 38, 39).
The amounts of polymerization were determined after 18 hour incubation under these
reaction conditions. The amounts of 7-Phos protein polymerization were normalized to their
corresponding wild-type values to obtain a percent change from wild-type (Figure 6A and
6B). The 7-Phos pseudohyperphosphorylation mutation affected the 3R isoforms differently
than it affected the 4R isoforms. The three 3R isoforms all showed a decrease in
polymerization measured by ThS staining (Figure 6A) and a greater than 50% decrease in
polymerization measured by LLS intensity (Figure 6B). In contrast, the 4R isoforms all had
increased polymerization levels with the 7-Phos mutation according to ThS fluorescence
(Figure 6A) and an increase or very little change in LLS values (Figure 6B).
Pseudohyperphosphorylation affects the number and the morphology of tau filaments
differently among the six isoforms
Samples of polymerization reactions under near optimal conditions (Figure 6) were
examined by transmission electron microscopy to determine whether the 7-Phos mutation
affected filament morphology (Figure 7). The mutation had varying effects on both the
morphology and number of filaments present, although no changes were apparent in
filament width or structure at higher magnification (data not shown). In general, filaments
for the 7-Phos proteins were fewer in number, larger in size, and formed similar or less total
mass of filaments (Figure 8). The exceptions were 0N4R 7-Phos (more filaments, more total
mass) (Figure 8A and 8C), and 2N3R (shorter filaments) (Figure 8B). It should be
mentioned that part of the effect seen on the number and morphology of 0N4R tau filaments
is likely due to uneven distribution of wild type filaments, which is lessened by GSK-3β
phosphorylation and is therefore likely to be decreased for 7-Phos 0N4R (33).
7-Phos affects the kinetics of polymerization
Polymerization reactions were monitored by LLS over time to measure the kinetics of
polymerization. Wild-type 3R isoforms had very long lag times before polymerization was
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detected (Figure 9A-C), while the 4R isoforms had shorter lag times and reached maximum
polymerization within approximately 80 minutes (Figure 9D-F).
The maximum amount of polymerization was greatly decreased for the 3R 7-Phos isoforms
compared to their wild-type counterparts (Figure 9A-C). As expected, very little
polymerization was detected for the 3R 7-Phos isoforms by LLS and the data could not be
fit to a kinetics equation (see Figure 5A-C). In contrast, the maximum amount of
polymerization for the 4R 7-Phos isoforms were similar to or increased over their wild-type
versions (Figure 9G) although their lag times before significant polymerization were longer
(Figure 9H). The rate of polymerization was also slower (Figure 9I).
The ability of the protein to stabilize tubulin polymerization is affected by
pseudohyperphosphorylation mutations
One of the normal functions of tau is the stabilization of microtubule assembly (1, 40–42).
Phosphorylation of the protein can decrease its affinity for microtubules as well as its ability
to induce the polymerization of tubulin dimers into microtubules (43–46). An in vitro
microtubule polymerization assay was used to measure the effect of the 7-Phos
pseudohyperphosphorylation mutation on the ability of each isoform to stabilize tubulin
polymerization (Figure 10A-F).
The 7-Phos mutation inhibited the ability of all six tau isoforms to stabilize the
polymerization of tubulin. The rates of tubulin polymerization were decreased (Figure 10G),
the lag times required to initiate microtubule polymerization were increased (Figure 10H),
and the amounts of overall tubulin polymerization were reduced (Figure 10I). Of these, 7-
Phos 0N4R seemed to be the least affected in all aspects.
DISCUSSION
The major common feature among neurodegenerative tauopathies is the polymerization of
the tau protein into filamentous aggregates. While these aggregates are present in all
tauopathies, the diseases can differ in the combination of tau isoforms included. The various
combinations of isoforms present within the tangles can be used to classify the
neurodegenerative tauopathies (7), indicating aggregation selectivity of certain isoforms in
particular tauopathies. The causes of selective aggregation of tau isoforms are unknown but
it is possible that phosphorylation plays an important role.
Phosphorylation of tau has long been associated with aggregation of tau in
neurodegenerative tauopathies. The pathological tau found in neurofibrillary tangles is often
hyperphosphorylated (47, 48). Kinases, such as GSK-3β, may display increased activity in
Alzheimer’s disease (49) and are associated with neurofibrillary tangles (50). In addition,
the activities of phosphatases, such as PP2A, are decreased in many tauopathies (51, 52).
The phosphorylation of tau can have profound effects on its conformation. Although tau
typically exists as a natively unfolded protein, it has been shown to adopt a global hairpin
conformation with the N- and C-termini folding over to interact with its MTBR (24).
Pseudophosphorylation at certain sites can affect the compaction of the protein (30, 53).
Because the isoforms of tau differ from each other by up to 89 amino acids (20–25%), it is
reasonable that similar levels or similar patterns of phosphorylation could have significantly
different effects on the isoform conformations and functions.
Pseudophosphorylation can provide a useful way to explore the effects of site-specific
phosphorylation on the conformation and function of a protein. However, we also recognize
that it may not exactly replicate an actual phosphorylation event and all of its effects. While
limitations exist and caution should be used in interpreting implications of the results,
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pseudophosphorylation can be a valuable tool to explore site-specific effects of
phosphorylation and, indeed, has been used in multiple in vitro and cell culture studies of tau
(23, 53–55).
In one such study, it has previously been reported that pseudophosphorylation mutations at
seven sites on full-length 2N4R tau replicated certain characteristics associated with
hyperphosphorylated tau (27). One of these characteristics was an SDS-resistant
electrophoretic mobility shift, likely due to a conformational change in the protein altering
the accessibility of the protein backbone to SDS. The pseudophosphorylation mutations at
the seven sites also negatively affected the normal interaction of the protein with
microtubules compared to wild-type 2N4R tau (27). In addition, the 7-Phos mutation
affected the in vitro polymerization of the isoform by inducing longer, but less frequent,
filament formation (27). We therefore sought to determine whether the same level and
pattern of pseudophosphorylation mutations would have different effects on the function of
the other tau isoforms.
In this study we have shown that pseudophosphorylation at seven identical sites on the
backbone of the six tau isoforms resulted in an SDS-resistant electrophoretic shift in each
protein, indicating that the conformation of the proteins had been altered by the 7-Phos
mutation. However, the magnitude of these changes was not equal. Previous studies have
shown that pseudophosphorylation of 2N4R tau at the S199, S202, S205, T212, S214, S396,
and S404 sites induce conformational changes that increase the reaction of the protein with
the conformational-dependent antibody MC1, an antibody that recognizes pathological tau
associated with electrophoretic shifts (53, 56). However, there are conflicting results as to
whether this pseudophosphorylation is causing a tightening or a loosening of the hairpin
conformation (30, 53). Our results could coincide with either model but it seems likely that a
global compaction of tau conformation would result in regions of tau becoming inaccessible,
thereby reducing SDS binding and slowing electrophoretic migration. Our results would
suggest that the level of compaction caused by pseudophosphorylation is not the same for
the six isoforms, indicating that similar levels and sites of phosphorylation have different
effects on the conformation of tau isoforms. These differential effects on conformation could
lead to changes in the other properties of the protein.
In support of this, pseudohyperphosphorylation affected the ARA induction of tau
polymerization differently among the isoforms. The 7-Phos 3R isoforms did not polymerize
as well as their wild-type counterparts while 7-Phos 4R isoforms polymerized as well or
better than wild-type 4R. This, combined with the differences in electrophoretic mobility,
suggests the possibility that the MTBR of the 3R isoforms may be less accessible to ARA
when they are in a conformation induced by the 7-Phos mutation. Previous results showing
that the MTBR of tau isoforms differ from one another both structurally and mechanistically
support this supposition (57). It is possible that different results could be obtained using
different inducer molecules such as heparin, planar aromatic dyes, polyanionic
microspheres, mRNA or alkyl sulfate detergents. While intriguing, we feel that these
analyses are beyond the scope of the current manuscript and are more appropriate for future
experimentation.
Because hyperphosphorylated tau is associated with aggregation in AD and other
tauopathies we might expect that pseudophosphorylation would lead to increased
polymerization in our in vitro reactions. However, for most of the isoforms, polymerization
was similar or decreased compared to the corresponding wild-type isoforms. This could be
due to the limitations of pseudophosphorylation as a model or the homogenous reactions
give different results than a mixture of phosphorylated forms of tau. However, it is also
possible that similar phosphorylation patterns could lead to different conformational effects
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on the isoforms. The varied conformational effects could then lead to increased aggregation
for some isoforms while decreasing the likelihood of aggregation for others. Variable
conformational changes could help explain why the isoform content of aggregates can vary
by tauopathy.
Compaction of the carboxy-terminus toward the MTBR would be expected to inhibit tau
aggregation (58, 59), while compaction of the amino-terminus toward the MTBR would be
expected to enhance tau aggregation (38, 53). If this is the case, inhibition caused by
compaction of the carboxy-terminus would likely be relatively similar among the isoforms
since that region does not differ between them. However, the compaction of the amino
terminus caused by phosphorylation would be expected to be different between the isoforms
due to the presence or absence of exons 2 and 3, and we would therefore expect this
compaction of the amino terminus to have more varied effects on polymerization of the
isoforms. Indeed, polymerization of the 0N 7-Phos isoforms seems to be less inhibited
compared to its wild-type counterparts than was observed for the 1N and 2N isoforms. In
fact, polymerization of the 0N4R 7-Phos in enhanced compared to wild-type 0N4R tau
under certain conditions. The absence of exons 2 and 3 could lead to a tighter compaction of
the amino-terminus when these sites in the proline-rich region are phosphorylated. This
tighter compaction could then lead to increased tau aggregation.
In general, the four-repeat isoforms seem to be less affected by pseudo-phosphorylation and
compaction than the three-repeat isoforms, presumably due to the additional MTBR. This
additional repeat reduces the impact of conformational-dependent enhancement or inhibition
of tau aggregation leading to similar aggregation for wild-type and 7-Phos of each isoforms.
It is likely that the additional repeat either results in a structural conformation that protects
the MTBR from the amino and carboxy terminals, or that the additional repeat provides a
second site for inducer interactions, thereby overcoming inhibition or enhancement by mass
action.
Other differences in the polymerization of 7-Phos isoforms existed at the optimal ratio of 2
μM protein and 75 μM ARA. All of the 7-Phos isoforms polymerized more slowly than
wild-type and fewer, but longer, filaments were formed for many of the 7-Phos isoforms.
This also suggests that compaction due to phosphorylation could negatively affect the ARA-
induced nucleation of filaments but could also stabilize filament elongation. This
compaction could be differentially affecting the accessibility of the MTBR as discussed
above, resulting in less nucleation and slower growth, causing the differences in morphology
observed between isoforms. The effect was greatest in 0N4R tau which displayed an
increase in polymerization, number of filaments formed, and length of filaments with the 7-
Phos pseudophosphorylation mutation. Part of this effect could be due to increased or
improved filament distribution on the electron microscopy grids (33) but the agreement
between the SDS-PAGE migration, quantitative electron microscopy, LLS, and ThS
fluorescence data suggest that the 0N4R 7-Phos has a more accessible MTBR.
Differences in accessibility of the MTBR would be expected to affect the ability of tau to
stabilize microtubule polymerization as well. The 7-Phos mutation caused a reduction in the
ability of all six isoforms to stabilize microtubules. The overall amount of tubulin
polymerization was decreased, the lag times were increased, and the rate of polymerization
was decreased. The degrees of changes were not equal among the isoforms. For example,
0N4R tau had much less severe defects in its ability to stabilize microtubules. Additionally,
the 0N3R 7-Phos stabilized microtubule growth more readily than the other 3R 7-Phos
isoforms did. This indicates that phosphorylation of 0N isoforms could cause the MTBR to
be more accessible than in 1N or 2N isoforms. In general, pseudohyperphosphorylated 4R
isoforms had more similar aggregation and microtubule stabilization characteristics as
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compared to their wild-type counterparts than the 3R isoforms. This indicates that
compaction of tau due to phosphorylation may be obscuring the MTBRs more for 3R
isoforms than 4R isoforms.
In summary, our results are consistent with similar levels and patterns of phosphorylation
having substantially different effects on tau isoforms. This result is important considering
efforts to target phosphorylation as a therapeutic intervention for tauopathies. Our results
suggest that such therapies will have different effects on the six isoforms of tau which could
lead to complications. They also suggest that animal models used to study the effects of
phosphorylation on the toxicity of tau would be affected by the choice of isoforms. Future
studies will be required to determine whether these results are specific to these sites and this
inducer or whether similar results will be obtained using alternative inducers or different
sites to generate alternative pseudohyperphosphorylated versions of tau isoforms.
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Figure 1. 7-Phos induces an SDS-resistant electrophoretic shift in all tau isoforms
(A) Six isoforms of tau are created through alternative mRNA splicing of the second, third
and tenth exons. The latter contains the second of four microtubule-binding regions.
Pseudophosphorylation mutations were made at seven sites commonly phosphorylated in
Alzheimer’s disease. This combination of mutations is referred to as 7-Phos. (B) 1 μg of the
wild-type and 7-Phos variants for each of the six isoforms separated via 10% SDS-PAGE.
MW refers to the molecular weight markers. The isoforms are labeled above the lanes with
WT indicating wild-type protein and 7P indicating 7-Phos protein for each isoform. (C) The
same amount of protein loaded onto a 10% SDS-PAGE with 6 M urea. (D) The mean values
of the electrophoretic shifts (y-axis, in kDa) for each isoform (labeled below x-axis)
separated via 10% SDS-PAGE. These values were calculated by subtracting the apparent
molecular weight of wild-type isoforms from the apparent molecular weight of the
corresponding 7-Phos isoforms. Bars represent the mean shift from three gels with the
standard deviation.
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Figure 2. Polymerization of varied tau concentrations measured by thioflavin S staining
Wild-type (closed circles •) and 7-Phos tau isoforms (open squares □) polymerization
reactions with 0 to 4 μM protein (x-axis) and 75 μM arachidonic acid were measured by
thioflavin S fluorescence (y-axis) after 18 hours incubation at 25 °C. Individual graphs are
shown for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R isoforms.
Bars represent the mean from 3 experiments ± standard deviation.
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Figure 3. Polymerization of varied tau concentrations measured by right-angle laser light
scattering
Wild-type (closed circles •) and 7-Phos tau isoform (open squares □) polymerization
reactions with 0 to 4 μM protein (x-axis) and 75 μM arachidonic acid were measured by
intensity of right-angle laser light scattering (y-axis) after 18 hours incubation at 25 °C.
Individual graphs are shown for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and
(F) 2N4R isoforms. Data are the mean from 3 experiments and bars represent ± s.d.
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Figure 4. Polymerization of 2 μM tau with 0 to 150 μM ARA measured by thioflavin S
fluorescence
Wild-type (closed circles •) and 7-Phos tau isoform (open squares □) polymerization
reactions with 2 μM protein and 0 to 150 μM arachidonic acid (x-axis) were measured by
thioflavin S fluorescence (y-axis) after 18 hours incubation at 25 °C. The fluorescence value
of the 0 μM ARA reaction was subtracted from the other values. Individual graphs are
shown for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R isoforms.
Bars represent ± s.d. from 3 experiments.
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Figure 5. Polymerization of 2 μM tau induced with varied ARA concentration (0 μM to 150 μM)
measured by right-angle laser light scattering
Wild-type (closed circles •) and 7-Phos tau isoform (open squares □) polymerization
reactions with 2 μM protein (x-axis) and 0 to 75 μM arachidonic acid were measured by
intensity of right-angle laser light scattering (y-axis) after 18 hours incubation at 25 °C.
Individual graphs are shown for (A) 0N3R, (B) 1N3R, (C) 2N3R, (D) 0N4R, (E) 1N4R, and
(F) 2N4R isoforms. Bars represent ± s.d. from 3 experiments.
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Figure 6. Percent change in polymerization of 2 μM 7-Phos protein and 75 μM ARA
polymerization reactions as compared to wild-type protein
Polymerization reactions were prepared with 2 μM tau and 75 μM ARA and incubated for
18 hours at 25 °C. Polymerization was measured by (A) ThS fluorescence and (B) right-
angle laser light scattering as described earlier. Results for each isoform are labeled on X-
axis. Bars represent the average from 3 experiments ± s.d.
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Figure 7. Electron Micrographs of 2 μM protein and 75 μM ARA polymerization reactions
Representative electron micrographs of polymerization reactions of wild-type isoforms
(left): (A) 0N3R, (C) 1N3R, (E) 2N3R, (G) 0N4R, (I) 1N4R, and (K) 2N4R; and
corresponding 7-Phos isoforms (right): (B) 0N3R, (D) 1N3R, (F) 2N3R, (H) 0N4R, (J)
1N4R, and (L) 2N4R. The images were taken at a magnification of 3600x and the scale bar
in (L) represent 1 μm and applies to all images.
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Figure 8. Quantitation of filaments from transmission electron micrographs
Quantitation of transmission electron micrographs from Figure 7 were performed as
described in Materials and Methods. Values for (A) total number of filaments, (B) average
filament length (μm), and (C) total length (number x average length) are shown for wild-
type (black bars) and 7-Phos (white bars) for each isoform (labeled on x-axis). Data
represent average values from 3 separate experiments ± s.d.
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Figure 9. Kinetics of tau polymerization
Polymerization reactions were monitored by right-angle laser light scattering (arbitrary
units, y-axis) at specific time points (minutes, x-axis) until the amount of polymerization
approached an apparent steady-state. The experiment was repeated three times for the wild-
type (closed circles •) and 7-Phos (open squares □) of (A) 0N3R, (B) 1N3R, (C) 2N3R, (D)
0N4R, (E) 1N4R, and (F) 2N4R. The equations were fit to the Gompertz equation and (G)
the maximum amount of polymerization, (H) the lag time, and (I) the polymerization rate
(kapp) for each was calculated. Isoforms are labeled on the x-axis. Data is shown as
normalized values to the amount of wild-type polymerization (percent change from wild-
type_ for three separate trials. Error bars represent the s.d. from 3 experiments. Data is not
included for the 3R isoforms in (H) and (I) because the data could not be satisfactorily fit to
the kinetics equation.
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Figure 10. Tau isoform stabilization of microtubule polymerization
The ability of wild-type (•) and 7-Phos (□) tau isoforms to stabilize the polymerization of
tubulin into microtubules was measured using a fluorescence assay. The relative
fluorescence units (y-axis) are plotted against time (x-axis) for (A) 0N3R, (B) 1N3R, (C)
2N3R, (D) 0N4R, (E) 1N4R, and (F) 2N4R. Data points represent 3 separate trials ± s.d. The
data was normalized to paclitaxel controls (crosshatches) that were performed in addition to
tau reactions. Tau/tubulin reactions did not contain paclitaxel. Kinetics parameters were
calculated from each of the three trials and the means of the percent change from wild-type
with the addition of 7-Phos for (G) the kapp, or polymerization rate, (H) lag time, or the time
from initiation of the reaction until polymerization is detected, and (I) the maximum
polymerization after 60 minutes are shown ± s.d.
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